Sanofi has announced a significant strategic decision to halt the development and forgo filing for approval of its immunology therapy, amlitelimab, for the treatment of atopic dermatitis (AD). This move represents a considerable setback for the pharmaceutical giant’s ambitions to secure a pipeline successor for its blockbuster eczema drug, Dupixent (dupilumab), as the latter approaches patent expiry. The decision, following a comprehensive strategic review, stems from Sanofi’s assessment that amlitelimab, an OX40 ligand blocker, would not offer "meaningful improvements" over the current standard of care (SoC) for AD. While the drug demonstrated efficacy in its Phase III program, it notably failed to meet its co-primary endpoint in the COAST 2 study (NCT06181435). This outcome has led to broader skepticism among analysts regarding the potential for the OX40 drug class to establish a significant foothold in the first-line AD market.
This discontinuation in AD marks another significant hurdle for amlitelimab’s market trajectory. The drug was once viewed as a promising candidate to fill the void left by Dupixent, a cornerstone of Sanofi’s immunology portfolio, which has generated billions in revenue. Prior to this decision, Sanofi had already ceased development programs for amlitelimab in other indications, including asthma, alopecia, and hidradenitis suppurativa (HS), signaling a pattern of challenges for the therapy.
Strategic Rationale and Market Landscape
The decision by Sanofi to discontinue amlitelimab’s development at the pre-registration stage for atopic dermatitis, while perhaps surprising to some, is likely influenced by the highly competitive and rapidly evolving landscape of AD treatments. The market is already well-served by established therapies and a robust pipeline of novel agents. Sanofi’s internal evaluation would have weighed amlitelimab’s demonstrated efficacy against the existing and emerging treatment options, including other biologics, small molecules, and topical therapies. The company’s stated rationale – that the drug does not offer "meaningful improvements" – suggests that even if effective, its incremental benefit may not justify the investment in a lengthy and costly regulatory and commercialization process, particularly when competing against established and well-tolerated treatments.
The atopic dermatitis market is a significant and growing segment within dermatology, with projections indicating substantial expansion in the coming years. Market research reports forecast the global AD market to reach approximately $22.4 billion by 2033, driven by increasing prevalence, a better understanding of the disease’s pathophysiology, and the development of more targeted therapies. This expanding market, while offering opportunities, also intensifies competition. For a new entrant to succeed, especially as a potential successor to a drug as successful as Dupixent, it needs to demonstrate clear clinical superiority, a favorable safety profile, and a compelling value proposition for both patients and healthcare providers.
A Timeline of Challenges for Amlitelimab
Sanofi’s journey with amlitelimab has been marked by a series of strategic adjustments and developmental setbacks, painting a picture of a therapy struggling to find its definitive place in the therapeutic armamentarium.
- Early Promise and Broad Development: Initially, amlitelimab was identified as a potential blockbuster candidate, prompting Sanofi to explore its utility across multiple inflammatory conditions. This included extensive research and development efforts in atopic dermatitis, asthma, alopecia areata, and hidradenitis suppurativa.
- Phase III Setback in Atopic Dermatitis: The crucial COAST 2 study, designed to evaluate amlitelimab’s efficacy and safety in moderate-to-severe AD, unfortunately, failed to meet its co-primary endpoint. This outcome was a significant turning point, raising doubts about the drug’s ability to differentiate itself in a crowded market.
- Discontinuation in Other Indications: Prior to the AD decision, Sanofi had already terminated development programs for amlitelimab in asthma, alopecia, and hidradenitis suppurativa. These earlier decisions, while not fully detailed publicly, likely reflected similar strategic considerations, perhaps related to efficacy, safety, or market potential in those specific disease areas.
- Strategic Review and Final Decision on AD: Following the COAST 2 results and a broader evaluation of its pipeline, Sanofi undertook a strategic review. This culminated in the recent decision not to proceed with regulatory filings or further development of amlitelimab for atopic dermatitis.
This series of events underscores the rigorous and often challenging nature of drug development, where promising early-stage results do not always translate into successful late-stage clinical trials or commercially viable products.
The Broader Impact on the OX40 Drug Class
The discontinuation of amlitelimab in atopic dermatitis is not an isolated event but rather part of a broader trend of challenges facing the OX40 drug class. This class of therapies targets the OX40 receptor, a co-stimulatory molecule expressed on activated T cells, which plays a role in immune responses. The rationale behind targeting OX40 is to modulate these immune responses in various inflammatory and autoimmune conditions.
However, the OX40 class has recently encountered significant headwinds, casting a shadow over its future prospects. A prominent example is Kyowa Kirin’s development program for rocatinlimab, another OX40 receptor blocker. Kyowa Kirin terminated its development of rocatinlimab after several patients treated with the drug developed Kaposi sarcoma, a rare cancer of the blood vessel walls. This serious safety concern has understandably heightened scrutiny on other OX40-targeting agents, including amlitelimab.
According to Tanuj Sircar, Associate Director of Competitive Intelligence at GlobalData, the safety concerns, particularly the emergence of malignancies like Kaposi sarcoma, likely cast a significant shadow over amlitelimab’s safety profile. Such adverse events can severely erode a drug’s perceived value and franchise potential, even if the efficacy data is otherwise positive. He notes that prior to Sanofi’s decision, two patients treated with amlitelimab had reportedly developed Kaposi’s sarcoma, as documented in a publication in Frontiers.
Sircar further commented, "Amlitelimab’s discontinuation draws parallels to its peer, rocatinlimab, and the discontinuation of both assets prior to filing will likely damage stakeholder perception of the class." This sentiment suggests that the setbacks experienced by multiple OX40-targeting drugs are creating a ripple effect, potentially dampening investor and industry enthusiasm for the entire therapeutic category.
Despite these challenges, the field is not entirely devoid of activity. Sircar points out that "Industry momentum for OX40s will likely wind down, though Inmagene’s non-depleting anti-OX40-R, IMG-007, is in Phase IIb development and it remains to be seen if AbbVie will continue development of Apogee’s OX40L, APG990." This indicates that while the broader class faces scrutiny, some specific agents with potentially differentiated mechanisms of action or safety profiles may continue to be explored. The "non-depleting" nature of IMG-007, for example, might suggest a different immunomodulatory profile that could mitigate some of the safety concerns associated with depleting OX40 therapies.
Future Strategic Directions for Sanofi
With the discontinuation of amlitelimab in AD, Sanofi is expected to reallocate its resources and strategic focus towards other promising areas within its immunology pipeline and beyond. Industry observers suggest that the company will likely intensify its efforts to maximize the value of Dupixent, its current market-leading therapy for AD and other atopic conditions, as it navigates the period leading up to patent expiry. This could involve exploring new indications, expanding its geographic reach, or developing next-generation formulations or delivery methods for Dupixent.
Furthermore, Sircar theorizes that Sanofi will redirect its investments towards oral modalities for AD. This includes its collaborations with emerging biotechnology companies focused on novel mechanisms of action. Specifically, Sanofi is actively involved with Kymera Therapeutics in the development of KT-485, an IRAK4 degrader, and has acquired rights to NX-3911, a STAT6 degrader from Nurix Therapeutics. Oral therapies offer potential advantages in terms of patient convenience and accessibility compared to injectable biologics, and Sanofi’s investment in these areas signals a commitment to exploring diverse therapeutic approaches for AD.
A Glimmer of Hope for Amlitelimab in Celiac Disease
Despite the setbacks in AD and other indications, amlitelimab may yet find a therapeutic niche. Sanofi remains committed to advancing the drug’s development in celiac disease, a chronic autoimmune disorder affecting the small intestine. The company is currently progressing with a Phase II study for amlitelimab in celiac disease, with anticipated results expected in the latter half of 2026. Celiac disease presents a different immunological challenge than atopic dermatitis, and the efficacy and safety profile of amlitelimab in this indication will be closely watched. The distinct immunological pathways involved in celiac disease could potentially offer a more favorable environment for amlitelimab’s therapeutic activity and safety. The success of this trial could significantly alter the perception of amlitelimab and salvage its future as a therapeutic agent.
The decision by Sanofi to discontinue amlitelimab’s development in atopic dermatitis underscores the intense competition and high bar for success in the pharmaceutical industry, particularly in well-established therapeutic areas like eczema. While this marks a significant disappointment for the company’s pipeline ambitions, its continued exploration of amlitelimab in celiac disease and its strategic investments in oral therapies for AD demonstrate a forward-looking approach to addressing unmet medical needs. The future of the OX40 drug class remains uncertain, but the ongoing research into specific agents and Sanofi’s diversified strategy offer insights into the evolving landscape of immunology and dermatological therapeutics.
